Literature DB >> 32108046

Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.

Kenichi Yanaka1, Alicia Guillien2, Thibaud Soumagne3, Justin Benet4, Nicolas Piliero1, François Picard5, Christophe Pison4, Olivier Sitbon6,7,8, Hélène Bouvaist1, Bruno Degano9,10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32108046     DOI： 10.1183/13993003.02418-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  6 in total

1.  Transition from epoprostenol to selexipag in a patient with systemic sclerosis and pulmonary hypertension during the postoperative period of colon cancer surgery: A case report.

Authors:  Takuma Tsuzuki Wada; Kazuhiro Yokota; Shinichiro Iida; Yuki Kanno; Nozomi Shinozuka; Kojiro Sato; Yu Funakubo Asanuma; Keiji Yamamoto; Toshihide Mimura
Journal:  J Scleroderma Relat Disord       Date:  2021-12-20

2.  Real-world experience of selexipag titration in pulmonary arterial hypertension.

Authors:  Sarah Cullivan; Anandan Natarajan; Niamh Boyle; Ciara McCormack; Sean Gaine; Brian McCullagh
Journal:  Br J Cardiol       Date:  2021-07-14

3.  An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report.

Authors:  Ayako Chida-Nagai; Takao Tsujioka; Daisuke Sasaki; Gaku Izumi; Hirokuni Yamazawa; Atsuhito Takeda
Journal:  Front Pediatr       Date:  2022-06-17       Impact factor: 3.569

4.  Long-term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension.

Authors:  Yuichi Tamura; Asuka Furukawa; Yudai Tamura; Kenta Yamada; Hirohisa Taniguchi; Keiichi Fukuda; Akio Kawamura; Toru Satoh
Journal:  Pulm Circ       Date:  2022-03-17       Impact factor: 2.886

5.  Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series.

Authors:  Sarah Blissett; David Blusztein; Vaikom S Mahadevan
Journal:  Eur Heart J Case Rep       Date:  2020-11-07

6.  Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.

Authors:  Xiaopei Cui; Weida Lu; Deyuan Zhang; Liangyi Qie; Haijun Li; Xiao Li; Hui Liu; Qiushang Ji
Journal:  Front Cardiovasc Med       Date:  2022-09-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.